Skip to Main Content

Paper Details

Capsid Inhibition with Lenacapavir in Multidrug-Resistant HIV-1 Infection.
New England Journal of Medicine
59
2022
CD4+, Capsid, ClinicalTrials, HIV, HIV-1, Lenacapavir, M66I, Multidrug-Resistant HIV-1 Infection, Patients, RNA, capsid, human, lenacapavir, multidrug-resistant HIV-1 infection, multidrug-resistant human immunodeficiency virus type 1 (HIV-1) infection, patients
Author NameAffiliation
Edwin DeJesusGermany (H.-J.S.) Vita-Salute University, San Raffaele Scientific Institute, Milan (A.C.) Prism Health North Texas (G.I.S.) and North Texas Infectious Diseases Consultants (M.B.) - both in Dallas Bamrasnaradura Infectious Diseases Institute, Thailand (K.S.) Ruane Clinical Research Group, J.M.B.) - both in California the University of Paris and the Department of Infectious Diseases, St. Louis-Lariboisiere Hospitals, Assistance Publique-Hopitaux de Paris
Hans-Jürgen StellbrinkGermany (H.-J.S.) Vita-Salute University, San Raffaele Scientific Institute, Milan (A.C.) Prism Health North Texas (G.I.S.) and North Texas Infectious Diseases Consultants (M.B.) - both in Dallas Bamrasnaradura Infectious Diseases Institute, Thailand (K.S.) Ruane Clinical Research Group, J.M.B.) - both in California the University of Paris and the Department of Infectious Diseases, St. Louis-Lariboisiere Hospitals, Assistance Publique-Hopitaux de Paris
  • 1 - 2

Datasets

Release 1.2